Amgen may be evaluating Cytokinetics bid; CYTK wants $130 $145 a share report

Shidlovski/iStock via Getty Images Another US pharma giant is speculated to be circling Cytokinetics ( NASDAQ: CYTK ) amid a WSJ report that Novartis ( NVS ) has decided to walk away from its pursuit of the biotech firm. There's speculation that Amgen ( AMGN ) may be interested in acquiring Cytokinetics ( CYTK ), according to a Betaville "uncooked alert." Johnson & Johnson ( JNJ ) is also speculated to indicate interest in CYTK, with its offer including a Contingent Value Right.

Novartis ( NVS ) may have decided to back out of a Cytokinetics ( CYTK ) deal as there's speculation that the CYTK board was holding out for $130 to $145 a share, according to Betaville, which cited people following the matter. Betaville first reported about Cytokinetics takeover speculation in late October, saying at the time that it was working with an investment bank after getting takeover interest.

Cytokinetics ( CYTK ) shares pared some of an earlier decline of as much as 28% and are now down 18%. More on Cytokinetics Cytokinetics: Clear Win For Aficamten In SEQUOIA HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript Cytokinetics plunges amid no deal announcement, Novartis backing away (update) Novartis said to have backed away from a deal for Cytokinetics.